ICUI
Bearish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
ICU Medical, Inc.
- Nom
- ICU Medical, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NASDAQ
- Capitalisation
- $4.2B
- Employés
- 13,000
- PDG
- Vivek Jain
- Site web
- https://www.icumed.com
- Marché
- BAXBDXKRMDTFX
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 378 titres (~68 978,12 $ US)
- Insiders
- FINNEY ELISHA W
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,514,786
Avg sell (VWAP, 90d window) $179.44 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,428,930 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-03 | Sanzone Virginia Ruth | Sell · S · 10b5-1 | 692 | $171.51 | $118,688 | Form 4 |
| 2026-09-01 | Bonnell Brian Michael | Sell · S · 10b5-1 | 6,381 | $175.00 | $1,116,675 | Form 4 |
| 2026-08-31 | Bonnell Brian Michael | Sell · S · 10b5-1 | 1,113 | $173.91 | $193,567 | Form 4 |
| 2026-08-13 | Woolson Daniel | Sell · S | 5,417 | $181.33 | $982,265 | Form 4 |
| 2026-08-12 | Sousa Ben | Sell · S | 2,250 | $178.32 | $401,209 | Form 4 |
| 2026-08-11 | FINNEY ELISHA W | Sell · S | 378 | $182.48 | $68,978 | Form 4 |
| 2026-08-11 | Voigtlander Christian B. | Sell · S | 8,929 | $182.93 | $1,633,404 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-05-06 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-06 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2024-10-31 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2022-02-14 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-12-23 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-09-25 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-09-24 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2020-09-23 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-03-31 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
ICUI presents a compelling earnings catalyst with a significant Q2 2026 beat ($2.37 vs $1.91 EPS) and analyst upgrades, supported by growing institutional confidence, justifying a moderately elevated event-driven score.
The first sentence of the analysis written for ICUI on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.36 · operating margin 4.8%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 36.8% | 34.6% | 32.8% | 30.6% | 37.3% | |
| Ebit Margin | 4.9% | 1.7% | 1.1% | -1.9% | 9.4% | |
| Ebitda Margin | 14.6% | 1.8% | 11.2% | 8.4% | 17.0% | |
| Operating Profit Margin | 4.8% | 1.8% | 1.0% | -1.9% | 9.4% | |
| Pretax Profit Margin | 0.1% | -2.8% | -3.5% | -5.0% | 9.4% | |
| Continuous Operations Profit Margin | 0.0% | -4.9% | -1.3% | -3.3% | 7.8% | |
| Net Profit Margin | 0.0% | -4.9% | -1.3% | -3.3% | 7.8% | |
| Bottom Line Profit Margin | 0.0% | -4.9% | -1.3% | -3.3% | 7.8% | |
| Current Ratio | 2.360 | 2.593 | 2.535 | 2.498 | 5.129 | |
| Quick Ratio | 1.126 | 1.541 | 1.062 | 1.090 | 3.684 | |
| Solvency Ratio | 0.114 | -0.051 | 0.088 | 0.066 | 0.765 | |
| Cash Ratio | 0.617 | 0.555 | 0.528 | 0.422 | 2.753 | |
| Price To Earnings Ratio | 4,803.704 | -32.126 | -81.089 | -50.637 | 48.835 | |
| Price To Earnings Growth Ratio | -47.743 | -0.110 | 1.341 | 0.309 | 2.902 | |
| Forward Price To Earnings Growth Ratio | -47.743 | -0.110 | 1.341 | 0.309 | 2.902 | |
| Price To Earnings Diluted Ratio | 4,852.721 | -32.126 | -81.089 | -50.637 | 50.072 | |
| Price To Earnings Diluted Growth Ratio | -48.234 | -0.110 | 1.341 | 0.306 | 2.796 | |
| Price To Book Ratio | 1.655 | 1.926 | 1.132 | 1.798 | 3.114 | |
| Price To Sales Ratio | 1.576 | 1.589 | 1.064 | 1.649 | 3.824 | |
| Price To Free Cash Flow Ratio | 38.292 | 30.357 | 33.128 | -23.280 | 27.006 | |
| Price To Operating Cash Flow Ratio | 19.547 | 18.547 | 14.457 | -60.499 | 18.812 | |
| Debt To Assets Ratio | 0.344 | 0.391 | 0.389 | 0.384 | 0.024 | |
| Debt To Equity Ratio | 0.656 | 0.835 | 0.802 | 0.830 | 0.028 | |
| Debt To Capital Ratio | 0.396 | 0.455 | 0.445 | 0.454 | 0.027 | |
| Long Term Debt To Capital Ratio | 0.381 | 0.438 | 0.426 | 0.437 | 0.000 | |
| Financial Leverage Ratio | 1.907 | 2.139 | 2.062 | 2.161 | 1.164 | |
| Working Capital Turnover Ratio | 2.851 | 2.931 | 3.053 | 2.905 | 1.701 | |
| Operating Cash Flow Ratio | 0.361 | 0.367 | 0.345 | -0.126 | 1.333 | |
| Operating Cash Flow Sales Ratio | 0.081 | 0.086 | 0.074 | -0.027 | 0.203 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.510 | 0.611 | 0.436 | 2.599 | 0.697 | |
| Debt Service Coverage Ratio | 2.314 | -0.055 | 1.964 | 2.305 | 237.071 | |
| Interest Coverage Ratio | 1.015 | 0.403 | 0.222 | -0.606 | 143.642 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.187 | 4.001 | 3.259 | -2.093 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.129 | 0.124 | 0.098 | -0.036 | 5.939 | |
| Capital Expenditure Coverage Ratio | 2.043 | 2.571 | 1.774 | -0.625 | 3.296 | |
| Dividend Paid And Capex Coverage Ratio | 2.043 | 2.571 | 1.774 | -0.625 | 3.296 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 14.086 | 119.109 | 15.215 | 27.587 | 20.251 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 36.8% | ▲2.1% | ▲2.3% |
| Ebit Margin | 4.9% | ▲3.2% | ▲1.8% |
| Ebitda Margin | 14.6% | ▲12.8% | ▲4.0% |
| Operating Profit Margin | 4.8% | ▲3.0% | ▲1.8% |
| Pretax Profit Margin | 0.1% | ▲2.9% | ▲0.5% |
| Continuous Operations Profit Margin | 0.0% | ▲5.0% | ▲0.4% |
| Net Profit Margin | 0.0% | ▲5.0% | ▲0.4% |
| Bottom Line Profit Margin | 0.0% | ▲5.0% | ▲0.4% |
| Current Ratio | 2.360 | ▼-0.232 | ▼-0.663 |
| Quick Ratio | 1.126 | ▼-0.416 | ▼-0.575 |
| Solvency Ratio | 0.114 | ▲0.165 | ▼-0.083 |
| Cash Ratio | 0.617 | ▲0.062 | ▼-0.358 |
| Price To Earnings Ratio | 4803.704 | ▲4835.830 | ▲3865.966 |
| Price To Earnings Growth Ratio | -47.743 | ▼-47.634 | ▼-39.083 |
| Forward Price To Earnings Growth Ratio | -47.743 | ▼-47.634 | ▼-39.083 |
| Price To Earnings Diluted Ratio | 4852.721 | ▲4884.847 | ▲3904.933 |
| Price To Earnings Diluted Growth Ratio | -48.234 | ▼-48.124 | ▼-39.453 |
| Price To Book Ratio | 1.655 | ▼-0.270 | ▼-0.270 |
| Price To Sales Ratio | 1.576 | ▼-0.012 | ▼-0.364 |
| Price To Free Cash Flow Ratio | 38.292 | ▲7.936 | ▲17.192 |
| Price To Operating Cash Flow Ratio | 19.547 | ▲0.999 | ▲17.374 |
| Debt To Assets Ratio | 0.344 | ▼-0.047 | ▲0.037 |
| Debt To Equity Ratio | 0.655 | ▼-0.180 | ▲0.025 |
| Debt To Capital Ratio | 0.396 | ▼-0.059 | ▲0.041 |
| Long Term Debt To Capital Ratio | 0.382 | ▼-0.057 | ▲0.045 |
| Financial Leverage Ratio | 1.907 | ▼-0.232 | ▲0.021 |
| Working Capital Turnover Ratio | 2.851 | ▼-0.080 | ▲0.163 |
| Operating Cash Flow Ratio | 0.360 | ▼-0.006 | ▼-0.095 |
| Operating Cash Flow Sales Ratio | 0.081 | ▼-0.005 | ▼-0.003 |
| Free Cash Flow Operating Cash Flow Ratio | 0.510 | ▼-0.101 | ▼-0.460 |
| Debt Service Coverage Ratio | 2.314 | ▲2.369 | ▼-46.406 |
| Interest Coverage Ratio | 1.015 | ▲0.612 | ▼-27.920 |
| Short Term Operating Cash Flow Coverage Ratio | 5.187 | ▲1.187 | ▲3.117 |
| Operating Cash Flow Coverage Ratio | 0.129 | ▲0.005 | ▼-1.122 |
| Capital Expenditure Coverage Ratio | 2.043 | ▼-0.528 | ▲0.231 |
| Dividend Paid And Capex Coverage Ratio | 2.043 | ▼-0.528 | ▲0.231 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 14.086 | ▼-105.023 | ▼-25.164 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.52B | $3.78B | $2.40B | $3.76B | $5.03B | |
| Enterprise value | $4.60B | $5.12B | $3.85B | $5.28B | $4.53B | |
| EV / Sales | 2.06x | 2.15x | 1.71x | 2.32x | 3.44x | |
| EV / Op. cash flow | 25.57x | 25.08x | 23.18x | -85.05x | 16.91x | |
| EV / Free cash flow | 50.10x | 41.05x | 53.12x | -32.73x | 24.28x | |
| EV / EBITDA | 14.09x | 119.11x | 15.21x | 27.59x | 20.25x | |
| Net debt / EBITDA | 3.32x | 31.03x | 5.72x | 7.96x | -2.27x | |
| Current ratio | 2.36x | 2.59x | 2.54x | 2.50x | 5.13x | |
| Income quality | 245.69x | -1.73x | -5.60x | 0.84x | 2.59x | |
| Graham number | $8 | — | — | — | $91 | |
| Graham net-net | -$48 | -$61 | -$63 | -$70 | $26 | |
| Tax burden | 23.1% | 178.3% | 37.9% | 64.9% | 83.7% | |
| Interest burden | 2.9% | -162.9% | -320.5% | 262.4% | 99.2% | |
| Working capital | $678.6M | $885.8M | $739.4M | $740.6M | $829.0M | |
| Invested capital | $3.32B | $3.56B | $3.77B | $3.89B | $1.57B | |
| Return on assets | 0.0% | -2.8% | -0.7% | -1.6% | 5.5% | |
| Operating ROA | 2.6% | 1.0% | 0.5% | -1.3% | 6.8% | |
| Return on tangible assets | 0.0% | -5.8% | -1.5% | -3.6% | 6.3% | |
| Return on equity | 0.0% | -6.0% | -1.4% | -3.6% | 6.4% | |
| Return on invested capital | 0.7% | 1.2% | 0.2% | -0.7% | 6.1% | |
| Return on capital employed | 3.0% | 1.2% | 0.6% | -1.1% | 7.3% | |
| Earnings yield | 0.0% | -3.1% | -1.2% | -2.0% | 2.0% | |
| Free cash flow yield | 2.6% | 3.3% | 3.0% | -4.3% | 3.7% | |
| Capex / Op. cash flow | 49.0% | 38.9% | 56.4% | -159.9% | 30.3% | |
| Capex / Depreciation | 43.9% | 33.0% | 40.9% | 42.2% | 90.5% | |
| Capex / Sales | 3.9% | 3.3% | 4.1% | 4.4% | 6.2% | |
| SG&A / Sales | 28.0% | 26.8% | 26.9% | 26.7% | 23.0% | |
| R&D / Sales | 3.9% | 3.7% | 3.8% | 4.1% | 3.6% | |
| Stock comp / Sales | 2.5% | 2.0% | 1.8% | 1.6% | 2.1% | |
| Intangibles / Total assets | 52.7% | 51.7% | 53.5% | 53.9% | 12.3% | |
| Days sales outstanding | 30d | 31d | 29d | 40d | 35d | |
| Days payables outstanding | 40d | 35d | 36d | 50d | 36d | |
| Operating cycle | 189d | 168d | 200d | 200d | 163d | |
| Cash conversion cycle | 149d | 133d | 164d | 150d | 127d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-09 California State Teachers Retirement System Grows Position in ICU Medical, Inc. $ICUI California State Teachers Retirement System grew its stake in shares of ICU Medical, Inc. (NASDAQ: ICUI) by 25.2% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,512 shares of the medical instruments supplier''s stock after purchasing an additional 5,536 shares during the period.
- 2026-08-07 ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings ICU Medical Inc (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.
- 2026-08-07 ICU Medical, Inc. (ICUI) Q2 2026 Earnings Call Transcript ICU Medical, Inc. (ICUI) Q2 2026 Earnings Call Transcript
- 2026-08-06 ICU Medical Q2 Earnings Call Highlights ICU Medical NASDAQ: ICUI reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis, as growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture deconsolidation.
- 2026-08-06 ICU Medical (ICUI) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for ICU Medical (ICUI) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-06 ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates ICU Medical (ICUI) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $2.1 per share a year ago.
- 2026-08-06 ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2026.
- 2026-07-23 ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call SAN CLEMENTE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2026 earnings release and conference call.
- 2026-07-09 Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America This expansion of IV solutions manufacturing will help enhance supply-chain resiliency, support portfolio development and advance non-DEHP innovation for the North American IV solutions market. Joint venture announces over $500M IV solutions manufacturing expansion in Austin, TX Expansion aimed at improving IV solutions supply resiliency and quality, and accelerating non-DEHP new product development in North America via fully automated technology First major milestone toward fulfilling the commitments of the joint venture finalized in May 2025 between ICU Medical, Inc. and Otsuka Pharmaceutical Factory America, Inc. AUSTIN, Texas, July 9, 2026 /PRNewswire/ -- Otsuka ICU Medical LLC today announced plans for an over $500 million expansion to its US IV solutions manufacturing through a new facility and significant upgrades to its existing operations in Austin, Texas.
- 2026-07-08 ICUI vs. SYK: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?